Genetic and pharmacological inhibition of MCT1 has been an effective strategy for targeting highly glycolytic tumors, inhibiting tumor growth through a combination of effects including accumulation of intracellular lactate, altering the production of glycolytic intermediates, reducing glucose transport and ATP levels, and reducing glutathione levels [33, 37, 41–43]. This evidence concerns the gene SLC16A1 and neoplasm.